• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Kyprolis (carfilzomib) - Articles and news items

kyprolis

Amgen submits sNDA for Kyprolis in relapsed multiple myeloma

Industry news / 23 July 2015 / Victoria White

Amgen has submitted a sNDA to the US FDA for Kyprolis to seek an expanded indication for the treatment of patients with relapsed multiple myeloma…

REVLIMID

FDA grants Amgen priority review for Kyprolis for the treatment of relapsed multiple myeloma

Industry news / 31 March 2015 / Victoria White

Amgen has announced that the FDA has accepted the sNDA of Kyprolis for the treatment of patients with relapsed multiple myeloma…

Amgen

Phase 3 head-to-head ENDEAVOR study demonstrates superiority of Kyprolis® (carfilzomib) over Velcade® (bortezomib) in patients with relapsed multiple myeloma

Industry news / 2 March 2015 / Amgen

Study met primary endpoint of progression-free survival patients receiving Kyprolis lived twice as long without disease progression…

Amgen

EMA accepts marketing authorisation application of Amgen’s kyprolis® (carfilzomib) for the treatment of relapsed multiple myeloma

Industry news / 2 March 2015 / Amgen

Amgen and its subsidiary Onyx Pharmaceuticals, Inc., today announced that the European Medicines Agency has accepted the Marketing Authorization Application (MAA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy…

Amgen

Amgen announces top-line results from Phase 3 focus trial of kyprolis® in patients with relapsed and advanced refractory multiple myeloma

Industry news / 15 August 2014 / Amgen

Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., announced that the Phase 3 clinical trial FOCUS did not meet its primary endpoint of improving overall survival…

Amgen

Amgen announces Phase 3 ASPIRE trial of Kyprolis® in patients with relapsed multiple myeloma met primary endpoint

Industry news / 4 August 2014 / Amgen

Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE met its primary endpoint of progression-free survival…

Amgen

Amgen and Onyx Data at ASCO 2014 highlight oncology pipeline and portfolio

Industry news / 28 May 2014 / Amgen

New data reinforces commitment to personalized medicine and highlights advances in immunotherapy platform…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +